Last reviewed · How we verify
TUMS
TUMS, marketed by Merck Sharp & Dohme LLC, is an over-the-counter antacid that provides quick relief from heartburn and indigestion. Its key strength lies in its rapid action and well-established brand recognition. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | TUMS |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evolve China PMCF Study
- A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (PHASE1,PHASE2)
- Breath Hydrogen and Methane as Biomarkers of Fiber Intake (NA)
- PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition (PHASE2)
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (PHASE2)
- Combined Effects of Statins and Exercise on Training Sensitive Health Markers (NA)
- Gait Training for Concurrent Optimization of Weight Mgt,bp Regulation and Functional Mobility (NA)
- Real-World NeuroModulate: Investigating Non-Invasive Brain Stimulation for Neuropsychiatric Disorders at TUM
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |